Study drug for young people with recurring brain glioma
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1/2 trial tests a study treatment for children and young adults under 22 whose brain glioma has come back or isn’t responding to prior treatment. It’s designed to see whether the treatment is safe and effective for shrinking tumors in this situation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age is under 22 years old, and the tumor is a specific type of brain glioma that has relapsed or is refractory (or a diffuse intrinsic brainstem glioma by brain scan).
- You have at least one confirmed and measurable tumor area doctors can track.
- Your general health score is adequate (Karnofsky or Lansky score 60 or higher).
- Your recent treatment timing and medicines fit the rules (no chemotherapy in the 3 weeks before starting; no growth-factor medicines in the 1 week before starting).
- Your blood and organ test results are within limits (neutrophils and platelets are high enough; liver, kidney, and blood-clotting numbers are not too abnormal).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a targeted medicine approach for high-grade glioma (a fast-growing brain tumor) and some diffuse midline tumors, including DIPG. It may help by matching treatment to tumor biology using tumor testing done before or around starting standard therapy.
This Phase 3 study tests a treatment plan after surgery to improve brain function and quality of life in adults with newly diagnosed, specific types of brain tumors (gliomas). It may help you keep thinking clearly and living better while your tumor is treated with standard medicines.
This Phase 3 trial tests whether delivering a cancer drug directly into brain blood vessels, along with standard radiation and temozolomide, works better than standard treatment alone in newly diagnosed glioblastoma (GBM). The goal is to improve control of the tumor while comparing side effects between the two approaches.
This study tests FT536, a new cell-based treatment, for people with a specific type of brain cancer (WHO Grade 4 astrocytoma) that has come back after standard treatment. The trial combines the new therapy with surgery to see if it can help stop the cancer from growing further.
This trial tests a new drug called ADI-PEG 20 combined with standard treatments (temozolomide and radiation) for children and young adults with newly diagnosed high-grade glioma. It aims to see if this combination is safe and effective.
This trial studies how brain tumors (like high-risk gliomas, medulloblastoma, and ependymoma) respond to treatment and why they sometimes become resistant. It is for young people aged 15 to 39 and aims to use tumor tissue samples to understand the tumor better and guide future therapies.
Hear when a new Glioblastoma Multiforme trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.